Post archive for ‘Company Reports’
Will Inhibitex Be The Next Big Acquisition in the HCV Space ? (INHX, $10.69)
Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11 billion), an 89% premium to last Friday’s close. Gilead will be paying for the acquisition with cash on hand and debt. Relative to alternatives such as investing money in short term debt instruments or doing […]
Gilead Makes Bid for Pharmasset: Could Achillion Be Next in Big Pharma’s Acquisition Gun Sights (ACHN, $6.00)
Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11 billion), an 89% premium to last Friday’s close. Gilead will be paying for the acquisition with cash on hand and debt. Relative to alternatives such as investing money in short term debt instruments or doing […]
Gilead’s Acquisiton of Pharmasset Is Expensive But Great Strategic Move (GILD, $35.57)
Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11 billion), an 89% premium to last Friday’s close. Gilead will be paying for the acquisition with cash on hand and debt. Relative to alternatives such as investing money in short term debt instruments or doing […]
Physician Survey on Provenge is Encouraging, Upgrading Dendreon to Buy (DNDN, $6.55))
Introduction Over the last few months, I have been speaking to physicians and researchers who are using and studying Provenge. Based on my research, I am recommending purchase of Dendreon. This note summarizes the opinions of the diverse group of people that I listened to and interviewed. I have grouped their comments into four categories: […]
Cubist Makes Attractive Takeover Bid for Adolor (ADLR, $1.91)
Investment View of the Proposed Acquisition Cubist announced today that it had signed a definitive agreement to acquire Adolor. Adolor has been one of my four recommendations. My price target was $4.50 in 2013 based on sales and earnings of Entereg alone and before taking into account the potential for ADL5945. This acquisition gives current […]
Santarus Jumps Last Hurdle for Submitting NDA on Key Blockbuster Drug Budesonide MMX (SNTS, $2.79)
Investment Opinion and Overview For those of you who read my recent reports on Santarus, you will recall that I believe that budesonide MMX has the potential to be a blockbuster for Santarus and is the most important product in its pipeline. I think that it will be the primary driver of significant growth in […]
Management Guidance On Issues Key to Provenge’s Outlook (DNDN, $9.00)
Investment Opinion In the aftermath of the 70% meltdown in the price of Dendreon stock caused by sharp lowering in expected sales of Provenge in 2011, investors are struggling to balance the positives and negatives of the investment case. I believe that the essential starting point for arriving at a new investment thesis is to […]
An In-Depth Look at Santarus as it Develops a Promising Pipeline to Offset Patent Challenges to Existing Products (SNTS, $3.14)
Investment Overview Santarus was founded to commercialize Zegerid for the treatment of gastrointestinal reflux disease (GERD) and ulcers. It competed in the proton pump inhibitor class of drugs, which includes Nexium, Prilosec, Prevacid, Protonix and Aciphex. Despite being up against the sales forces of much larger companies like Astra-Zeneca (AZN), Abbott (ABT), Wyeth and Johnson […]
Transcept to Resubmit Intermezzo NDA; Hopes for a Class I Review (TSPT, $6.63)
Resubmission of Intermezzo NDA Transcept Pharmaceuticals in a press release today (September 15) said that it plans to resubmit its NDA on Intermezzo following a meeting with the FDA. The key parts of the resubmission are: Transcept proposes to reduce the recommended Intermezzo dose for women from 3.5 mg to 1.75 mg, and to […]
Check with Adolor Management on Entereg Marketing Transition and Progress of Partnering Discussions on ADL 5945 (ADLR, $2.05)
Investment Thesis I upgraded Adolor to a BUY after the company announced that it had reacquired all rights to Entereg from Glaxo. I did this even though binary phase II data on ADL 5945, their new drug for opioid induced constipation, was due at any time. I felt that the stock was attractive on the […]